Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Huntington's Disease - Pipeline Assessment and Market Forecasts
to 2017
Published on December 2010

Report Summary

Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Huntington's Disease - Pipeline Assessment and Market
Forecasts to 2017'. The report is an essential source of information and analysis on the global Huntington's disease therapeutics
market and pipeline. The report identifies the key trends shaping and driving the global huntington's disease therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the
market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products
within the global muscular dystrophy therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house
analysis by GlobalData's team of industry experts.

GlobalData has estimated the global Huntington's disease therapeutics market to be valued at $142 m in 2009. It is expected to
increase to $2 billion with a Compound Annual Growth Rate (CAGR) of 39.6 by 2017. There is a high unmet need in the current
Huntington's disease therapeutics market in terms of both safety and efficacy profile. New high potential drugs of Huntington's
disease therapeutics are expected to come in the market after 2017.

Scope

The report provides information on the key drivers and challenges of the Huntington's disease therapeutics market. Its scope
includes:
- Annualized global Huntington's disease therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.
Pipeline candidates fall under major classes such as nerve growth factor and doparmegenic neurons loss inhibitor
- Analysis of the current and future competition in the global Huntington's disease therapeutics market. Key market players covered
are Amarin Corporation and Medivation Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the
Huntington's disease therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Huntington's disease therapeutics market.

Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/6


- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global Huntington's disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Huntington's disease market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Huntington's Disease: Market Characterization 5
2.1 Overview 5
2.2 Huntington's Disease Therapeutics Market Size 6
2.3 Huntington's Disease Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Huntington's Disease Therapeutics Market 8
2.4.1 Drivers for the Huntington's Disease Therapeutics Market 8
2.4.2 Barriers for the Huntington's Disease market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 Huntington's Disease Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Huntington's Disease Therapeutics Market 12
3.3.1 Xenazine (tetrabenazine) 12
3.4 Key Takeaway 13
4 Huntington's Disease: Pipeline Assessment 14
4.1 Overview 14
4.2 Strategic Pipeline Assessment 14
4.2.1 Technology Trends Analytic Framework 14
4.3 Huntington's Disease Therapeutics ' Promising Drugs under Clinical Development 16
4.4 Molecule Profile for Promising Drugs under Clinical Development 17
4.4.1 AMR-101 (Miraxion, ethyl EPA) (Amarin Pharmaceuticals) 17
4.4.2 Dimebon (latrepirdine) (Medivation/Pfizer) 18
4.4.3 Coenzyme Q10 (CoQ) (National Institute of Neurological Disorders and Stroke - NINDS) 19
4.5 Huntington's Disease Therapeutics' Clinical Pipeline by Mechanism of Action 20
4.5.1 Huntington's Disease TherapeuticsPipeline ' Pipeline by Clinical Phases of Development 21
4.5.2 Huntington's Disease Therapeutics ' Phase III Clinical Pipeline 21
4.5.3 Huntington's Disease Therapeutics ' Phase II Clinical Pipeline 21
4.5.4 Huntington's Disease Therapeutics ' Phase I Clinical Pipeline 22
4.5.5 Huntington's Disease Therapeutics ' Preclinical Phase Pipeline 22
4.5.6 Huntington's Disease Therapeutics ' Discovery Pipeline 22



4.6 Key Takeaway 23
5 Huntington's Disease Therapeutics Market: Implications for Future Market Competition 24
6 Huntington's Disease Therapeutics Market: Future Players in the Huntington's Disease Market 26
6.1 Introduction 26
6.2 Amarin Corporation, Ireland 27
6.2.1 Overview 27
6.2.2 CNS Portfolio 27
6.2.3 Huntington's disease Portfolio 27
6.3 Medivation Inc., the US 28
6.3.1 Overview 28
6.3.2 CNS Portfolio 29
6.3.3 Huntington's Disease Portfolio 29
6.4 National Institute of Neurological Disorders and Stroke, the US 30
6.4.1 Overview 30
6.4.2 Huntington's Disease Portfolio 30
7 Huntington's Disease Market: Appendix 32
7.1 Market Definitions 32
7.2 Abbreviations 32
7.3 Research Methodology 33
7.3.1 Coverage 33
7.3.2 Secondary Research 34
7.3.3 Forecasting 34
7.3.4 Primary Research 37
7.3.5 Expert Panel Validation 37
7.4 Contact Us 37
7.5 Disclaimer 37
7.6 Sources 38
1.1 List of Tables
Table 1: Huntington's Disease Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Table 2: Huntington's Disease Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 7
Table 3: Major Marketed Product in the Huntington's Disease Therapeutics Market, 2010 13
Table 4: Huntington's Disease Therapeutics Market' Most Promising Drugs Under Clinical Development, 2010 16
Table 5: Huntington's Disease Therapeutics Market, Phase III Clinical Pipeline, 2010 21
Table 6: Huntington's Disease Therapeutics Market, Phase II Clinical Pipeline, 2010 21
Table 7: Huntington's Disease Therapeutics Market, Phase I Clinical Pipeline, 2010 22
Table 8: Huntington's Disease Therapeutics, Preclinical Phase Pipeline, 2010 22
Table 9: Huntington's Disease Therapeutics Market ' Discovery Pipeline, 2010 22
Table 10: Amarin, CNS Pipeline Products, 2010 27
Table 11: Amarin, Huntington's Disease Pipeline Products, 2010 27
Table 12: Medivation, CNS Pipeline Products, 2010 29
Table 13: Medivation, Huntington's Disease Pipeline Products, 2010 29
Table 14: NINDS, Huntington's Disease Pipeline Products, 2010 30
1.2 List of Figures
Figure 1: Huntington's Disease Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Figure 2: Huntington's Disease Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 7
Figure 3: Opportunity and Unmet Need in the Huntington's Disease Therapeutics Market 9
Figure 4: Strategic Competitor Assessment of the Marketed Products for the Huntington's Disease Therapeutics Market, 2010 11
Figure 5: Technology Trends Analytic Framework of the Huntington's Disease Therapeutics Market Pipeline, 2010 15



Figure 6: Technology Trends Analytic Framework of the Huntington's Disease Therapeutics Market Pipeline, Description, 2010 15
Figure 7: Huntington's Disease Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2010 20
Figure 8: Huntington's Disease Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2010 21
Figure 9: Implications for Future Market Competition in the Huntington's Disease Therapeutics Market, 2010 24
Figure 10: Huntington's Disease Therapeutics Market, Clinical Pipeline by Company, 2010 26
Figure 11: GlobalData Market Forecasting Model 36

Companies mentioned

Amarin Corporation, Ireland
Medivation Inc., the US
National Institute of Neurological Disorders and Stroke, the US


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Huntington's Disease - Pipeline Assessment and Market Forecasts to 2017